Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight loss in a Phase IIa study
It thinks its drying out, so it starts producing more oil to compensate
Key Takeaway: While precursors provide the building blocks, liposomal delivery provides the finished antioxidant in a form that the body can actually absorb and utilize without it being broken down during digestion
Notice Pregnancy or breastfeeding Active skin infection or HSV at the site Hypersensitivity to PLLA, CaHA, CMC, HA, hyaluronidase, or lidocaine Active autoimmune flare, immunosuppression, or recent radiation needs clearance Implanted electronic device in the Thermage RF field Therapeutic anticoagulation or recent dental work within 4 weeks timing reviewed Active rapid weight loss without plateau timing reviewed at consultation Session summary & comparison Related procedures Evidence & comparison guides Need another answer before deciding
Dose Escalation: A dose-escalation study helps establish the maximum tolerated dose, but it can be time-consuming and may require adaptive trial designs to efficiently reach optimal dosing levels
